Drugs / KELI-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06678399 | Apr 2025 → Oct 2026 expected | — | Kelifarma | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KELI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06678399 ↗ |
| Modality | Cell therapy | “KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.” NCT06678399 ↗ |
| Route | Intravenous | “Intravenous Administration” NCT06678399 ↗ |